SMF
LGND icon

Scott Marsh Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Scott Marsh Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$802K Buy
+7,051
New +$754K 0.3% 109

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scott Marsh Financial's LGND Position: Q2 2025 in Review

Scott Marsh Financial opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2025: 7,051 shares worth $802K. The stake represents 0.3% of the portfolio and ranks #109 among its holdings.

271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Scott Marsh Financial held 7,051 shares of Ligand Pharmaceuticals worth $802K as of Q2 2025.
  • Ligand Pharmaceuticals was a new Scott Marsh Financial position in Q2 2025.
  • Ligand Pharmaceuticals made up 0.3% of Scott Marsh Financial's portfolio in Q2 2025, its #109 holding.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Scott Marsh Financial's 13F filing for Q2 2025, filed 14 Aug 2025.